EXACT Sciences Co. (NASDAQ:EXAS) Director Katherine S. Zanotti sold 7,232 shares of the firm’s stock in a transaction dated Thursday, April 12th. The shares were sold at an average price of $45.00, for a total transaction of $325,440.00. Following the completion of the sale, the director now owns 105,814 shares in the company, valued at $4,761,630. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
EXAS opened at $44.96 on Monday. EXACT Sciences Co. has a 12-month low of $23.30 and a 12-month high of $63.60. The company has a quick ratio of 6.77, a current ratio of 7.15 and a debt-to-equity ratio of 0.01. The company has a market cap of $5,519.77, a price-to-earnings ratio of -45.41 and a beta of 0.87.
EXACT Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Thursday, February 22nd. The medical research company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.09. EXACT Sciences had a negative net margin of 43.01% and a negative return on equity of 24.13%. The company had revenue of $87.41 million during the quarter, compared to analyst estimates of $87.42 million. During the same period last year, the firm posted ($0.34) EPS. EXACT Sciences’s revenue for the quarter was up 148.0% compared to the same quarter last year. analysts expect that EXACT Sciences Co. will post -0.92 EPS for the current year.
A number of research firms have recently weighed in on EXAS. Bank of America set a $67.00 price target on shares of EXACT Sciences and gave the company a “buy” rating in a report on Monday, January 8th. BidaskClub raised shares of EXACT Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, December 21st. Zacks Investment Research raised shares of EXACT Sciences from a “hold” rating to a “buy” rating and set a $62.00 price objective for the company in a research report on Tuesday, January 16th. William Blair reaffirmed a “buy” rating on shares of EXACT Sciences in a research report on Tuesday, January 2nd. Finally, Goldman Sachs began coverage on shares of EXACT Sciences in a research report on Monday, January 29th. They issued a “neutral” rating and a $51.00 price objective for the company. Seven research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $52.84.
EXACT Sciences Company Profile
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.